関連する実験動画
Updated: Jan 31, 2026
01:26
Acute Coronary Syndrome V: Nursing Management
Published on: June 19, 2025
325
プレビューです. 発達におけるストキャスティシティについて,鋭い見方.
Robert J Johnston1, Claude Desplan
1Department of Biology, New York University, 1009 Silver Center, 100 Washington Square East, New York, NY 10003, USA.
Cell
|March 10, 2010
まとめ
遺伝子発現の変動は,不完全な浸透性を持つCaenorhabditis elegans変異体において増加する. バイモダル反応は,上流の調節器の騒音が重要な値を超え,遺伝子調節に影響を及ぼすときに発生します.
科学分野:
- 遺伝学 遺伝学とは
- 発達生物学 発達生物学について
- 分子生物学は分子生物学である.
背景:
- 遺伝子発現は,生物の発達と機能に不可欠です.
- 遺伝子発現の多様性を理解することは,現象的差異を説明する鍵です.
- ゲノタイプが常に期待されるフェノタイプを生成しない不完全な浸透性は,遺伝学における課題を提示します.
研究 の 目的:
- 遺伝子発現の変異と不完全な穿透性との関係を調査する.
- ミュータントの遺伝子発現騒音の増加の原因となる分子機構を特定する.
- 現象型反応を誘発する上流の規制当局の役割を探求する.
主な方法:
- 単一のmRNA分子の定量化技術を使用しました.
- 野生型および変異型のCaenorhabditis elegansの遺伝子発現パターンを分析した.
- 規制上の値を特定するために,計算分析を用いた.
主要な成果:
- 不完全な穿透性を示す変異体における遺伝子発現変異の有意な増加を示した.
- アップストリームレギュレータのエクスプレッションノイズの臨界値を特定しました.
- この値を超えると,バイモダル遺伝子発現反応が誘発されることが示された.
結論:
- 不完全な穿透は,遺伝子発現の変動性の上昇と関連しています.
- アップストリーム調節遺伝子発現におけるノイズは,異なった現象的結果につながる可能性があります.
- この研究は,遺伝子調節と現象型変異を制御する定量的原理の洞察を提供します.
関連する概念動画
Acute Coronary Syndrome V: Nursing Management
325
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
325
Acute Coronary Syndrome IV: Interprofessional Care
288
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
288
Acute Coronary Syndrome III: Diagnostic Studies
268
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
268
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
427
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
427
Acute Coronary Syndrome I: Introduction
975
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
975
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.3K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K